Advaxis CEO Thomas A. Moore to Present at the 8th Annual BIO Investor Forum

Presentation Slated for Today, October 29, 2009 at 8:30 AM PDT

Webcast URL:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ADXS&item_id=2478420

NORTH BRUNSWICK, N.J.--(Business Wire)--
CEO Thomas A. Moore ofAdvaxis, Inc., (OTCBB: ADXS), the live, attenuated
Listeria monocytogenes (Lm) biotechnology company, will present at the 8th
Annual BIO Investors Forum at the Grand Hotel in San Francisco, CA.

The presentation will be webcast with a replay available beginning one-hour
after the presentation.

About the Company

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria
monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne
Paterson, professor of microbiology at the University of Pennsylvania and
chairperson of Advaxis` scientific advisory board. Advaxis is developing
attenuated live Lm vaccines that deliver engineered tumor antigens, which
stimulate multiple simultaneous immunological mechanisms to fight cancer.

In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against
the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15)
women with recurrent, advanced, metastatic cancer of the cervix. Although this
first trial of an Lm vaccine in humans was not designed or powered to prove
efficacy, Advaxis believes an efficacy signal was observed that will be further
explored in two (2) planned Phase II trials in the US and India in cervical
cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN).
Advaxis now has nine (9) distinct cancer fighting constructs in various stages
of development, both directly and with academic collaborators. For further
information on the Company, please visit: www.advaxis.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking
statements that involve risks and uncertainties.The statements contained herein
that are not purely historical are forward looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended.Forward-looking statements deal with
the Company`s current plans, intentions, beliefs and expectations and statements
of future economic performance.Forward-looking statements involve known and
unknown risks and uncertainties that may cause the Company's actual results in
future periods to differ materially from what is currently anticipated.Factors
that could cause or contribute to such differences include those discussed from
time to time in reports filed by the Company with the Securities and Exchange
Commission.The Company cannot guarantee its future results, levels of activity,
performance or achievements.

Advaxis, Incorporated
Conrad Mir, Chief Investment Officer
732-545-1590 (Office)
732-545-1084 (FAX)
info@advaxis.com
www.advaxis.com

Copyright Business Wire 2009